mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells Persist at 6 Months and Recognize the Delta Variant
Bezawit A. Woldemeskel, Caroline C. Garliss, Joel N. Blankson
Abstract
Little is known about the decay kinetics of coronavirus disease 2019 vaccine-elicited severe acute respiratory syndrome coronavirus 2-specific T cells. In this study we show a modest decline in the frequency of these T cells at 6 months and demonstrate robust expansion in response to antigen and recognition of spike peptides from the Delta variant.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusBetacoronavirus2019-20 coronavirus outbreakVirologyCoronavirus disease 2019 (COVID-19)Respiratory systemCoronaviridaeDeltaSevere acute respiratory syndromeImmunologyRespiratory diseaseInternal medicineLungOutbreakAerospace engineeringDiseaseEngineeringInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral gastroenteritis research and epidemiology